Currently, there are limited effective treatment options for pancreatic cancer—an aggressive disease that often presents in late stages when it is already locally advanced or involves metastases. One potential path forward in pancreatic cancer treatment is chimeric antigen receptor (CAR) T-cell therapy, which has had limited efficacy in this disease setting thus far, but is being studied in clinical trials. A recent review published in Molecular Therapy – Oncolytics highlighted ongoing trials of CAR T-cell therapy in pancreatic cancer and what the future may hold.
In pancreatic ductal adenocarcinoma (PDAC), which accounts for approximately 90% of pancreatic malignancies, there has been little progress in survival rates in recent years. As it stands, PDAC is on track to become the second leading cause of cancer-related deaths by 2030 if no significant improvements in treatment efficacy are made. Surgical removal is the only potentially curative treatment, but most patients are not eligible by the time it is detected. Read more . . .